1. Generics Bulletin
  2. >>Products

UK To Diverge On Biosimilar Data Requirements

Reduced Data Burden Welcome, But Industry Wants Global Approach

 
• By Ian Schofield

The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.

GUIDANCE CONCEPT
The MHRA is to issue new guidance on biosimilars • Source: Shutterstock

In a post-Brexit move towards regulatory divergence, the UK medicines agency, the MHRA, is about to issue a draft guideline that will reduce the UK clinical trial data requirements for biosimilar submissions.

MHRA head June Raine said the guideline, which would do away with the need for a comparative efficacy trial for biosimilars in most cases following the end of the Brexit transition period, would be issued for consultation in the coming weeks

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.